Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines

Immunogenetics

Volumn 59, Issue 2, 2007, Pages 123-133

  Rodriguez T ^a   Mendez R ^a   Del Campo, A ^a   Aptsiauri, N ^a   Martin J ^b   Orozco, G ^b   Pawelec, G ^c   Schadendorf, D ^d   Ruiz Cabello, F ^a   Garrido, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c Section for Transplantation Immunology and Immunohaematology   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CIITA; HLA class II; Melanoma; Polymorphism

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; TRANSACTIVATOR PROTEIN;

AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; DNA FLANKING REGION; DNA POLYMORPHISM; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA CELL; PRIORITY JOURNAL; PROMOTER REGION;

ALLELES; BASE SEQUENCE; CELL LINE, TUMOR; DNA PROBES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS II; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MELANOMA; NUCLEAR PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; TRANS-ACTIVATORS;

EID: 33846348639     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00251-006-0171-9     Document Type: Article

References (52)

1. Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, Trigo I, Garrido F, Ruiz-Cabello F (1998) Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 47:113-120
2. Andersen SN, Rognum TO, Lund E, Meling GI, Hauge S (1993) Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 68:80-85
3. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480
4. Bergman W, Ruiter DJ, Scheffer E, van Vloten WA (1988) Melanocytic atypia in dysplastic nevi. Immunohistochemical and cytophotometrical analysis. Cancer 61:1660-1666
5. Brocker EB, Suter L, Bruggen J, Ruiter DJ, Macher E, Sorg C (1985) Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 36:29-35
6. Brunner CA, Gokel JM, Riethmuller, Johnson JP (1991) Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognosis. Eur J Cancer 27:411-416
7. Cabrera T, Ruiz-Cabello F, Garrido F (1995) Biological implications of HLA-DR expression in tumors. Scand J Immunol 41:398-406
8. Chang CH, Flavell RA (1995) Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 181:765-767
9. Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA (1996) Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4:167-178
10. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F (1991) Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 2:47-54
11. D'Alessandro G, Zardawi I, Grace J, McCarthy WH, Hersey P (1987) Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma. Pathology 19:339-346
12. Douhan J, Lieberson R, Knoll JH, Zhou H, Glimcher LH (1997) An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator. J Exp Med 185:1885-1895
13. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M (1989) Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 49:5091-5096
14. Esteban F, Ruiz-Cabello F, Concha A, Perez-Ayala M, Sanchez-Rozas JA, Garrido F (1990) HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis 8:319-328
15. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109-119
16. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491-499
17. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95
18. Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G (2001) Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ 12:327-335
19. Harton JA, Ting JP (2000) Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 20:6185-6194
20. Hilton DA, West KP (1990) An evaluation of the prognostic significance of HLA-DR expression in gastric carcinoma. Cancer 66:1154-1157
21. Holling TM, Schooten E, Langerak AW, van den Elsen PJ (2004) Regulation of MHC class II expression in human T-cell malignancies. Blood 103:1438-1444
22. Holzmann B, Brocker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmuller G, Johnson JP (1987) Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 39:466-471
23. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A (2000) Induction of primary NYESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198-12203
24. Kern I, Steimle V, Siegrist CA, Mach B (1995) The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int Immunol 7:1295-1299
25. Krawczyk M, Reith W (2006) Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Tissue Antigens 67:183-197
26. Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F (1988) Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 5:203-212
27. Morimoto Y, Toyota M, Satoh A, Murai M, Mita H, Suzuki H, Takamura Y, Ikeda H, Ishida T, Sato N, Tokino T, Imai K (2004) Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br J Cancer 90:844-852
28. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B (1997) Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 16:2851-2860
29. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B (1998) Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8:157-166
30. Nagarajan UM, Bushey A, Boss JM (2002) Modulation of gene expression by the MHC class II transactivator. J Immunol 169:5078-5088
31. Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, Wang LD, Yang CS (2001) DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22:1615-1623
32. Ono SJ, Bazil V, Sugawara M, Strominger JL (1991) An isotype-specific trans-acting factor is defective in a mutant B cell line that expresses HLA-DQ, but not -DR or -DP. J Exp Med 173:629-637
33. Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D (2005) Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice. Clin Cancer Res 11:5241-5247
34. Pawelec G, Marsh SG (2006) ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol Immunother 55:623-627
35. Piskurich JF, Linhoff MW, Wang Y, Ting JP (1999) Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol 19:431-440
36. Reith W, LeibundGut-Landmann S, Waldburger JM (2005) Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 5:793-806
37. Ruiter DJ, Bhan AK, Harrist TJ, Sober AJ, Mihm MC Jr (1982) Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 129:2808-2815
38. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C, Ferrone S (1984) Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 44:3930-3935
39. Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H, Suzuki H, Sasaki Y, Kanaseki T, Takamura Y, Soejima H, Urano T, Yanagihara K, Endo T, Hinoda Y, Fujita M, Hosokawa M, Sato N, Tokino T, Imai K (2004) Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23:8876-8886
40. Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M (2003) CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol 170:1490-1497
41. Steimle V, Otten LA, Zufferey M, Mach B (1993) Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135-146
42. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, Lobell A, Khademi M, Borjesson O, Lindgren CM, Lundman P, Brookes AJ, Kere J, Luthman H, Alfredsson L, Hillert J, Klareskog L, Hamsten A, Piehl F, Olsson T (2005) MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 37:486-494
43. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619-628
44. Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H (1982) Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors. Am J Pathol 107:357-361
45. van den Elsen PJ, van der Stoep N, Vietor HE, Wilson L, van Zutphen M, Gobin SJ (2000) Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-gamma inducible promoter (PIV) of CIITA. Hum Immunol 61:850-862
46. van der Stoep N, Biesta P, Quinten E, van den Elsen PJ (2002) Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer 97:501-507
47. van Duinen SG, Mauw BJ, de Graaff-Reitsma CB, Ruiter DJ (1984) Methods in laboratory investigation. Immunoelectron microscopic methods for demonstration of antigens on normal human melanocytes and other epidermal cells. Lab Invest 50:733-741
48. van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S (1988) Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol 90:755-760
49. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S (1979) DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J Exp Med 149:658-668
50. Zaloudik J, Moore M, Ghosh AK, Mechl Z, Rejthar A (1988) DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol 41:1078-1084
51. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF (2001) CD4 (+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964-3969
52. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP (2000) Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol 20:6051-6061